[{"run_id":"20260906T231458-5fdd2fff","semester":"1272","observed_at":"2026-09-06 23:14:58.172943+00:00","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","course_id":"PHMSCI 770","course_uid":"course_3fccebda183122da4a95adb6","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","course_number":770,"subjects":["PHMSCI"],"title":"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I","description":"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes. Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels. Not open to students with credit for PHARMACY 770 prior to fall 2026.","requirements_text":"Declared in MS Pharmaceutical Sciences","official_learning_outcomes_json":"[]"},{"run_id":"20260907T155543-ce3781c4","semester":"1272","observed_at":"2026-09-07 15:55:43.033547+00:00","record_version_id":"3fe82b78da6106da037370637cb182711f649ef50c59fe8ba86c8554e0a230bf","course_id":"PHMSCI 770","course_uid":"course_3fccebda183122da4a95adb6","catalog_version_id":"f6477f279dae5c75278010d122a5ffa7397ded5a5db8c1ec0a762d14306f6467","course_number":770,"subjects":["PHMSCI"],"title":"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I","description":"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes. Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels. Not open to students with credit for PHARMACY 770 prior to fall 2026.","requirements_text":"Declared in MS Pharmaceutical Sciences","official_learning_outcomes_json":"[]"},{"run_id":"20261014T203208-0851c9a1","semester":"1274","observed_at":"2026-10-14 17:50:09.728220+00:00","record_version_id":"3ddf615594aad5b59aa7956995d2511a271a5afcf813978a8b45fc10086d6f3e","course_id":"PHMSCI 770","course_uid":"course_3fccebda183122da4a95adb6","catalog_version_id":"0cf9d39503f57a361961824645422b3c707ec8e9ae93ca29aa86cd5d41fcc6bd","course_number":770,"subjects":["PHMSCI"],"title":"CNS DRUG DESIGNS, ACTIONS, AND APPLICATIONS I","description":"Explores how chemical properties influence molecular targets in the central nervous system (CNS), how altered signaling drives physiological changes, and how cholinergic and glutamatergic pharmaceuticals improve patient outcomes. Develops skills in primary literature analysis to enable conceptual integration of information across chemical, molecular, cellular, systems, and societal levels. Not open to students with credit for PHARMACY 770 prior to fall 2026.","requirements_text":"Declared in MS Pharmaceutical Sciences","official_learning_outcomes_json":"[{\"catalog_year\":\"2026-2027\",\"observed_at\":\"2026-10-14T17:51:12.655724+00:00\",\"source\":\"catalog\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\",\"term\":null,\"text\":\"Identify CNS active drug classes and origins of cholinergic and glutamatergic drugs based in part on structural aspects of the molecule.\"},{\"catalog_year\":\"2026-2027\",\"observed_at\":\"2026-10-14T17:51:12.655724+00:00\",\"source\":\"catalog\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\",\"term\":null,\"text\":\"List physicochemical properties of drugs, anatomical structures and molecular machinery that influence drug access to and efflux from the CNS.\"},{\"catalog_year\":\"2026-2027\",\"observed_at\":\"2026-10-14T17:51:12.655724+00:00\",\"source\":\"catalog\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\",\"term\":null,\"text\":\"Describe the major neurotransmitters of the central nervous system, including their physiologic role, distribution, synthesis, storage, and release.\"},{\"catalog_year\":\"2026-2027\",\"observed_at\":\"2026-10-14T17:51:12.655724+00:00\",\"source\":\"catalog\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\",\"term\":null,\"text\":\"Recall the principal mechanisms by which receptors affect cellular signaling in the Central Nervous System.\"},{\"catalog_year\":\"2026-2027\",\"observed_at\":\"2026-10-14T17:51:12.655724+00:00\",\"source\":\"catalog\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\",\"term\":null,\"text\":\"Match psychiatric conditions and target symptoms of these conditions with appropriate cholinergic and glutamatergic pharmaceuticals.\"},{\"catalog_year\":\"2026-2027\",\"observed_at\":\"2026-10-14T17:51:12.655724+00:00\",\"source\":\"catalog\",\"source_url\":\"https://guide.wisc.edu/courses/phm_sci/\",\"term\":null,\"text\":\"Describe common / serious adverse effects of cholinergic and glutamatergic pharmaceuticals and methods for preventing or minimizing their occurrence.\"}]"}]